Dr. Chan specializes in the surgical and medical treatment of ovarian and other
pelvic cancers at CPMC. He is board certified in gynecologic oncology, and obstetrics
and gynecology. He is investigating new treatments for gynecologic cancers,
including targeted biologic therapies, and exploring the role of tumor-initiating
cells in ovarian cancer. A clinician and surgeon, Dr. Chan is a principal investigator
of studies assessing the treatment and health outcomes of ovarian and uterine cancer
patients.
Sutter Health Research Enterprise
1501 Trousdale Drive
Burlingame, CA, 94010
(415) 751-1847
ChanJK@Sutterhealth.org
Primary Research Interests
Related Clinical Trials
Locally Advanced or Metastatic (Immunogen Soraya)
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial
Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Fola
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD, Karolina Harger N.P.
Status: Active, Recruiting
Locally Advanced or Metastatic (NRG GY023)
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic
Agents
Investigator: John Chung-Kai Chan M.D.
Status: Active, Recruiting
Locally Advanced or Metastatic (Roche YO40482)
Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab
to Patients With Advanced Platinum-sensitive Ovarian Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Metastatic (NRG GY018)
Testing Addition of Immunotherapy Pembrolizumab to the Usual Chemotherapy Treatment
(Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Investigator: John Chung-Kai Chan M.D.
Status: Active, Recruiting
Metastatic (Sutro STRO-002-GM1)
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRa) Antibody Drug Conjugate in
Ovarian & Endometrial Cancers
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Metastatic or Locally Advanced (Agenus GOG 3028) (Temp Enrollment Hold)
Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line
Cervical Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Status: Active, Not Recruiting
Novocure Innovate3
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel
for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / IN
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Status: Active, Recruiting